Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene
about
The role of the ALK receptor in cancer biologyProgress in molecular-based management of differentiated thyroid cancerTargeting EML4-ALK driven non-small cell lung cancer (NSCLC)Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterationsDifferential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.Response and acquired resistance to everolimus in anaplastic thyroid cancerActivity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practiceInhibitors of the anaplastic lymphoma kinaseALK and NSCLC: Targeted therapy with ALK inhibitorsCytological results of ultrasound-guided fine-needle aspiration cytology for thyroid nodules: emphasis on correlation with sonographic findings.ALK-rearrangements and testing methods in non-small cell lung cancer: a reviewA Case of a Rapidly Enlarging Neck Mass with Airway Compromise.Molecular pathogenesis and mechanisms of thyroid cancerThe preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.ALK-driven tumors and targeted therapy: focus on crizotinibmRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switchGenetic alterations in poorly differentiated and undifferentiated thyroid carcinomasMolecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangementALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome.ALK-immunoreactive neoplasms.Mutations in critical domains confer the human mTOR gene strong tumorigenicity.Targeting ALK in neuroblastoma--preclinical and clinical advancements.Recent progress of genome study for anaplastic thyroid cancer.ALK: a tyrosine kinase target for cancer therapy.Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer.Treating ALK-positive lung cancer--early successes and future challenges.Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.Anaplastic lymphoma kinase as a therapeutic target.Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.ALK-positive cancer: still a growing entity.SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways.Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer.Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.Anaplastic lymphoma kinase: Role in cancer and therapy perspective.Neuroendocrine carcinoma of the lung expressing anaplastic lymphoma kinase on high-sensitivity immunohistochemistry: A case reportPerformance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer.An update of ALK inhibitors in human clinical trials.
P2860
Q26738384-C87A0C48-8401-42BB-B696-99A52801B992Q26999887-CD5C08B1-199D-4BA7-A7DC-6E90D31E541CQ27002155-3DA9AFA8-4125-4EC7-85E8-B863934CFD66Q27027491-25A23C9D-FEB9-4556-989F-E51D6F355C1BQ27851684-34DCC806-4E97-463D-AD62-9AFCA5BFFB97Q27852211-353D2F83-563B-43E6-9717-137C8DD9D6DAQ27853080-7961BF23-85D1-4CAF-8416-896DDDCB3CE8Q27853136-D3CC83F6-7BB5-4251-8984-AE4F66CAA1A4Q27853298-A5F39ADC-E351-446C-84DB-CCDD1A67A612Q28071903-D867D686-4766-4C9F-AE23-099D89BD3762Q28267124-6B94D7B9-27B9-4D6D-9D2A-EAEFD084A69BQ28393324-A378DB9F-A306-440A-8F1C-A96D05E43B9FQ30474213-F6DC887A-7C2B-4813-810C-7D76BD010154Q33776835-BDFEBF93-C752-4DA6-B6B6-F7285BBCB61AQ33832214-5500A7FE-15A5-48FE-86F5-7E1B7528F340Q34329018-D891BB8A-2495-4367-BFCB-397BDB5EFF8AQ34353920-293EE103-1963-403B-AA3C-97D9AB0132FCQ34414378-027404C0-3434-4E3F-9558-518B0F6E5A58Q34463393-CD819635-4EDD-4AEA-810D-8E7A2FDBECEFQ35731037-A2BBAA07-0B0E-4E4B-801F-6F5A540942EEQ35738399-39646453-7ABC-4735-A9E4-4ED3B1A327F0Q35768388-FA664412-C2E8-4256-9ECA-0E9B0D9F9B61Q36092957-1EE8E982-36D7-4A2E-941D-B45C3E48E31BQ36647365-8006B110-211B-42B9-80C3-1295F383433AQ36933081-E243A66C-3FC9-44EE-9069-4FB34264E076Q36992782-CAFBF37C-1198-4FC4-91E1-226B4EA68D67Q37518624-F46C64EB-1888-4E88-B068-7B20972C9BFBQ37660065-E1C2EC55-D329-4876-A31F-27C1D6CDA393Q37999657-82B8EFA3-47DA-4DE1-AA22-0917B44F3B55Q38042570-2BDA7910-6BE8-414C-A938-E1DD32F7975AQ38045455-4ED9C0C0-794C-4085-ABBD-E689CF0912AFQ38148969-F9AFB44B-6078-439C-BC90-62A314E3A1CBQ38184584-2B16D3F3-05B7-4AD1-AAAE-BC5EACA9FB59Q38262971-B42B8BEB-16BC-4582-90A0-B1A26D309C51Q38459398-4AA9816C-82FD-407E-9D19-25ABBF3A756EQ38484053-4DCFAFEC-722A-4E84-8537-128C7F00C055Q38623421-F4F38FFF-A993-484E-AB25-1E050CA85BC7Q38637925-40AE8A71-1E94-4D3A-A5B1-4B56FD7BD286Q38649524-4D6A7411-E50C-45CE-AC03-42489207BDF8Q38652927-1B7AD210-DFB5-4872-961E-350B587E9240
P2860
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene
@ast
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene
@en
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene
@nl
type
label
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene
@ast
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene
@en
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene
@nl
prefLabel
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene
@ast
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene
@en
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene
@nl
P2860
P3181
P1433
P1476
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene
@en
P2093
Avaniyapuram Kannan Murugan
Mingzhao Xing
P2860
P304
P3181
P356
10.1158/0008-5472.CAN-10-4041
P407
P577
2011-07-01T00:00:00Z